TP53 and glioma: In order to determine if chromothripsis was associated with the amplification of our identified modulators of TP53 and RB1 signaling, we tested for chromothripsis using Shatterproof on 18 tumors that included genomically stable non-small cell lung carcinomas (NSCLC; N=2) and low grade gliomas (IDH1 mutants; N=4) as putative negative controls in addition to high grade gliomas (N=12) (Figure 2a).